Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

被引：135

作者：

Costa, Ricardo ^{[1
]}

Shah, Ami N. ^{[3
]}

Santa-Maria, Cesar A. ^{[1
,2
]}

Cruz, Marcelo R. ^{[1
]}

Mahalingam, Devalingam ^{[4
,5
,6
]}

Carneiro, Benedito A. ^{[1
,2
]}

Chae, Young Kwang ^{[1
,2
]}

Cristofanilli, Massimo ^{[1
,2
]}

Gradishar, William J. ^{[1
,2
]}

Giles, Francis J. ^{[1
,2
]}

机构：

[1] Feinberg Sch Med, Div Hematol Oncol, Dev Therapeut Program, Chicago, IL USA

[2] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[3] Feinberg Sch Med, Div Hematol Oncol, Chicago, IL USA

[4] Univ Texas Hlth Sci Ctr San Antonio, Dept Med Canc Res, San Antonio, TX 78229 USA

[5] Univ Texas Hlth Sci Ctr San Antonio, Therapy Ctr, San Antonio, TX 78229 USA

[6] Univ Texas Hlth Sci Ctr San Antonio, Sch Med, San Antonio, TX 78229 USA

来源：

CANCER TREATMENT REVIEWS | 2017年 / 53卷

关键词：

Triple negative breast cancer; Epidermal Growth Factor Receptor; Targeted therapy; mTOR; CELL LUNG-CANCER; IXABEPILONE PLUS CAPECITABINE; PATHOLOGICAL COMPLETE RESPONSE; MONOCLONAL-ANTIBODY CETUXIMAB; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; OPEN-LABEL; PROTEIN EXPRESSION; CLINICAL-PRACTICE; SPORADIC BREAST;

D O I：

10.1016/j.ctrv.2016.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC. (C) 2017 Elsevier Ltd. All rights reserved.

引用

页码：111 / 119

页数：9

共 113 条

[1]

ALI SM, 2015, SAN ANT BREAST CANC

[2] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[3] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair [J].

Ashworth, Alan .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3785-3790

[4] Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma [J].

Baldassarre, G ;

Battista, S ;

Belletti, B ;

Thakur, S ;

Pentimalli, F ;

Trapasso, F ;

Fedele, M ;

Pierantoni, G ;

Croce, CM ;

Fusco, A .

MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (07) :2225-2238

[5] Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer [J].

Barrett, Michael T. ;

Anderson, Karen S. ;

Lenkiewicz, Elizabeth ;

Andreozzi, Mariacarla ;

Cunliffe, Heather E. ;

Klassen, Christine L. ;

Dueck, Amylou C. ;

McCullough, Ann E. ;

Reddy, Srikanth K. ;

Ramanathan, Ramesh K. ;

Northfelt, Donald W. ;

Pockaj, Barbara A. .

ONCOTARGET, 2015, 6 (28) :26483-26493

[6] ANTITUMOR EFFECTS OF DOXORUBICIN IN COMBINATION WITH ANTIEPIDERMAL GROWTH-FACTOR RECEPTOR MONOCLONAL-ANTIBODIES [J].

BASELGA, J ;

NORTON, L ;

MASUI, H ;

PANDIELLA, A ;

COPLAN, K ;

MILLER, WH ;

MENDELSOHN, J .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (16) :1327-1333

[7] Randomized Phase II Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatic Triple-Negative Breast Cancer [J].

Baselga, Jose ;

Gomez, Patricia ;

Greil, Richard ;

Braga, Sofia ;

Climent, Miguel A. ;

Wardley, Andrew M. ;

Kaufman, Bella ;

Stemmer, Salomon M. ;

Pego, Antonio ;

Chan, Arlene ;

Goeminne, Jean-Charles ;

Graas, Marie-Pascale ;

Kennedy, M. John ;

Ciruelos Gil, Eva Maria ;

Schneeweiss, Andreas ;

Zubel, Angela ;

Groos, Jutta ;

Melezinkova, Helena ;

Awada, Ahmad .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (20) :2586-+

[8] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[9] Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer [J].

Baselga, Jose ;

Cortes, Javier ;

Kim, Sung-Bae ;

Im, Seock-Ah ;

Hegg, Roberto ;

Im, Young-Hyuck ;

Roman, Laslo ;

Pedrini, Jose Luiz ;

Pienkowski, Tadeusz ;

Knott, Adam ;

Clark, Emma ;

Benyunes, Mark C. ;

Ross, Graham ;

Swain, Sandra M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (02) :109-119

[10] Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach [J].

Beger, C ;

Pierce, LN ;

Krüger, M ;

Marcusson, EG ;

Robbins, JM ;

Welcsh, P ;

Welch, PJ ;

Welte, K ;

King, MC ;

Barber, JR ;

Wong-Staal, F .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :130-135

← 1 2 3 4 5 6 7 8 9 10 →